Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of “Moderate Buy” by Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has received a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $5.17.

A number of research firms have recently commented on SGMO. Wells Fargo & Company reduced their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 31st. Truist Financial cut their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Jefferies Financial Group lowered their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, December 31st. StockNews.com cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, January 27th.

Institutional Trading of Sangamo Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC grew its position in shares of Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after acquiring an additional 1,528,600 shares in the last quarter. Golden State Equity Partners increased its stake in Sangamo Therapeutics by 2,592.3% during the fourth quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company’s stock valued at $332,000 after purchasing an additional 313,587 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Sangamo Therapeutics by 14.6% during the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after purchasing an additional 272,123 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Sangamo Therapeutics during the second quarter worth $89,000. Finally, Vontobel Holding Ltd. lifted its position in shares of Sangamo Therapeutics by 412.3% in the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 241,440 shares during the last quarter. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Stock Performance

Shares of Sangamo Therapeutics stock opened at $1.23 on Friday. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The stock has a market cap of $256.64 million, a price-to-earnings ratio of -1.64 and a beta of 1.29. The company has a fifty day moving average price of $1.73 and a 200 day moving average price of $1.34.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. The company had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same quarter in the prior year, the business earned ($0.34) earnings per share. Analysts forecast that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.